Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Adrian Minson, MBBS,FRACP,FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, David Ritchie, MB ChB, PhD FRACP, FRCPA, Piers Blombery, MBBS, John F. Seymour, Constantine S. Tam, MBBS, Michael Dickinson, DMed Sci

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138946

Published: 2020

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137603

Published: 2020

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Glen A Kennedy, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS,PhDFRACP,FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashish Misra, MBBS, FRACP, Elango Subramoniapillai, MBBS, FRACP, James Morton, MBBS, FRACP, FRCPA, Simon Durrant, FRCP,FRCPath,MBBS, Andrea S Hendon, MBBS, PhD FRACP, FRCPA, John Moore, MDFRACP,FRCPA, David Ritchie, MD PhD, David Gottlieb, MBBS, MD FRACP, FRCPA, Julian Cooney, FRACP,FRCPA,MBBS,, Luke Buizen, BSc (Hons), MSc, Sanjoy K Paul, PhD, Geoff R. Hill, MD

Blood (2019) 134 (Supplement_1): 368.

https://doi.org/10.1182/blood-2019-126285

Published: 2019

Journal Articles

Comparison of Dinakara and Cotes Method on Correction of Diffusion Limit of Carbon Monoxide and the Impact on Outcomes of Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI)

Tzu-Yang Wang, MBBS, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 5542.

https://doi.org/10.1182/blood.V130.Suppl_1.5542.5542

Published: 2017

Journal Articles

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Joel Wight, MBBS, Kathryn Jackson, MBBS, Ashanka Mahilal Beligaswatte, BA, MBBS, MD FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA, Louisa Martin, MBBS, Ian D. Lewis, MBBS PhD FRACP FRCPA, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Daniela Zantomio, FRACP, FRCPA, MBBS, Simon Z. He, MBBS,FRACP,FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Kirk Morris, FRACP FRCPA MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS

Blood (2016) 128 (22): 3989.

https://doi.org/10.1182/blood.V128.22.3989.3989

Published: 2016

Journal Articles

Early Acute Kidney Injury Post Allogeneic Hematopoetic Progenitor Cell Transplant Is Associated with Increased Risk of Gvhd, Higher Mortality and Reduced Survival

Andrew Birchley, BSc, MBBS, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashleigh Scott, MBBS, Cameron Curley, MBBS, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA

Blood (2016) 128 (22): 2227.

https://doi.org/10.1182/blood.V128.22.2227.2227

Published: 2016

Journal Articles

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Midori Nakagaki, BPharm, MSc, BCOP, Michael Barras, BPharm, GradDipClinPharm, PhD, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 1910.

https://doi.org/10.1182/blood.V126.23.1910.1910

Published: 2015

NARROW

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Comparison of Dinakara and Cotes Method on Correction of Diffusion Limit of Carbon Monoxide and the Impact on Outcomes of Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI)

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Early Acute Kidney Injury Post Allogeneic Hematopoetic Progenitor Cell Transplant Is Associated with Increased Risk of Gvhd, Higher Mortality and Reduced Survival

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only